Skip to main content
Premium Trial:

Request an Annual Quote

GeneOhm Completes $14M Second Closing of Series C; Round Now Totals $26M

NEW YORK, Jan. 18 (GenomeWeb News) - GeneOhm Sciences has raised $14 million in a second closing of a Series C venture capital financing round.


The San Diego-based firm, which develops tools for molecular diagnostic applications, completed a $12 million first closing of the Series C late last year when it merged with Infectio Diagnostic.


New investors Kaiser Permanente Ventures, QuestMark Partners, and Posco Bioventures participated in the financing round along with existing investors Domain Associates, SGF Sante, CHL Medical Partners, CB Health Ventures, and CDIB.


GeneOhm said the funds would be used to accelerate commercialization of its molecular diagnostics technology for infectious disease pathogens, genetic mutations linked to inherited diseases, and oncology.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.